SCHEMBL22200595

SCHEMBL22200595

CC(C)n1c(=O)c(-c2ccc(NSCCC(F)(F)F)c(F)c2)nc2cnc(NC3CCC(N(C)C)C(F)C3)nc21

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.49
MAPK8 P45983 13/20 0.33
MAPK10 P53779 11/20 0.33
MAPK9 P45984 10/20 0.33
MAPK14 Q16539 5/20 0.33
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD17B10 Q99714 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200592 0.92 ERN1 (0.55) ERN1MAPK8MAPK10MAPK9MAPK14
SCHEMBL22200742 0.89 ERN1 (0.49) ERN1MAPK8MAPK10MAPK9MEN1
SCHEMBL22200599 0.89 ERN1 (0.51) ERN1MAPK8MAPK10MAPK9MAPK14
SCHEMBL22190893 0.88 ERN1 (0.57) ERN1MAPK8MAPK10MAPK9MAPK14
SCHEMBL22200381 0.88 ERN1 (0.47) ERN1MAPK8MAPK10MAPK9MAPK14
SCHEMBL29357971 0.88 ERN1 (0.57) ERN1MAPK8MAPK10MAPK9MAPK14
SCHEMBL22200675 0.88 ERN1 (0.57) ERN1MAPK8MAPK10MAPK9MAPK14
SCHEMBL22200676 0.88 ERN1 (0.57) ERN1MAPK8MAPK10MAPK9MAPK14
Hydrochloric Acid SCHEMBL22191423 0.87 ERN1 (0.57) ERN1MAPK8MAPK10MAPK9MAPK14
Hydrochloric Acid SCHEMBL29354734 0.87 ERN1 (0.57) ERN1MAPK8MAPK10MAPK9MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed